Abstract：
:Chronic Lymphocytic Leukemia B cells (CLL) are malignant cells which retain at least some functions of normal B cells. Paramount amongst the latter is that when such cells are appropriately stimulated, they are able to present antigens, including any potential tumor antigens, making them excellent choices as a candidate tumor vaccine. We show that following stimulation of CLL cells with Phorbol myristic acetate, IL-2, the TLR7 agonist imiquimod (P2I) and ionomycin (P2Iio), markedly increased expression of CD54 and CD83 was seen, indicative of B cell activation and a transition to antigen-presenting cells. However, this occurred in the context of augmented expression of the known immunoregulatory molecule, CD200. Accordingly we explored the effect of stimulation of CLL cells with P2Iio, followed by coating of cells with a non-depleting anti-CD200mAb, on the ability of those cells to immunize PBL in vitro to become cytotoxic to CLL cells, or to protect NOD-SCIDγcnull (NSG) mice from subsequent CLL tumor challenge. Our data indicate that this protocol is effective in inducing CD8+ CTL able to lyse CLL cells in vitro, and decrease tumor burden in vivo in spleen and marrow of mice injected with CLL cells. Pre-treatment of mice with a CD8 depleting antibody before vaccination with P2Iio/anti-CD200 coated cells abolished any protection seen. These data suggest a potential role for blockade of CD200 expression on CLL cells as a component of a tumor vaccination strategy.
journal_name
Leuk Resjournal_title
Leukemia researchauthors
Zhu F,Khatri I,Spaner D,Gorczynski RMdoi
10.1016/j.leukres.2018.03.002subject
Has Abstractpub_date
2018-05-01 00:00:00pages
40-47eissn
0145-2126issn
1873-5835pii
S0145-2126(18)30055-9journal_volume
68pub_type
杂志文章abstract：:Immunophenotypic classification of the acute leukemias (AcL) is of well documented value in those of lymphoid or uncertain origin and of increasing importance in those of nonlymphoid origin. Most of these studies have been performed on viable cell suspensions. To study the efficacy of a simpler immunohistochemical app...
journal_title：Leukemia research
pub_type： 杂志文章
doi：10.1016/0145-2126(87)90080-4
更新日期：1987-01-01 00:00:00
abstract：:Imatinib mesylate (IM) is the treatment of choice in patients with newly diagnosed chronic myeloid leukemia (CML), irrespectively of their age. Nevertheless, information regarding tolerability and responses in advanced-age patients, a subgroup in which co-morbidities and other factors may influence outcome, is scarce,...
journal_title：Leukemia research
pub_type： 临床试验,杂志文章,多中心研究
doi：10.1016/j.leukres.2011.01.017
更新日期：2011-09-01 00:00:00
abstract：:The expression of various proto-oncogenes in primary culture of lymphocytes from peripheral blood of bovine with chronic lymphocytic leukemia (CLL) was studied. Cellular proto-oncogenes encode proteins that propagate growth, differentiation or apoptosis signals from cell membrane to nucleus. The proliferation and diff...
journal_title：Leukemia research
pub_type： 杂志文章
doi：10.1016/s0145-2126(97)00128-8
更新日期：1998-02-01 00:00:00
abstract：:Incorporation of ABL-targeted oral tyrosine kinase inhibitors (TKIs) into frontline therapeutic regimens has improved outcomes for adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph + ALL). However, patients with persistent minimal residual disease (MRD) exhibit increased risk of relapse. Co...
journal_title：Leukemia research
pub_type： 杂志文章
doi：10.1016/j.leukres.2019.02.009
更新日期：2019-04-01 00:00:00
abstract：:The classical myeloproliferative neoplasms (MPN) are comparatively uncommon in children and display a degree of mutational naivety if considering the high frequency of known MPN driver events observed in the corresponding adult diseases. Whole exome sequencing has unravelled much of the underlying molecular complexity...
journal_title：Leukemia research
pub_type： 信件
doi：10.1016/j.leukres.2014.06.003
更新日期：2014-08-01 00:00:00
abstract：:FLT3 is a receptor tyrosine kinase involved in the survival of hematopoietic stem cells, and mutations of FLT3 have been reported to be of prognostic significance. This is the first study of FLT3 mutations in pediatric non-promyelocytic AML patients that received the same treatment scheme in single institute. FLT3 int...
journal_title：Leukemia research
pub_type： 杂志文章
doi：10.1016/j.leukres.2004.11.006
更新日期：2005-06-01 00:00:00
abstract：:Deletion in chromosome 9p involving the CDKN2A locus (9p21.3) is known in many malignancies. To detect this deletion in adolescent ALL patients we used oligo array CGH and studied 54 patients aged 10-25 years. Deletion rate was 25/54 (46%), of these 19/25 (76%) were homozygous. Small deletions (<200 kb) were found in ...
journal_title：Leukemia research
pub_type： 杂志文章
doi：10.1016/j.leukres.2008.01.014
更新日期：2008-08-01 00:00:00
abstract：:Aven expression has recently been identified as an anti-apoptotic protein. In this study, Aven expression in 91 children with acute lymphoblastic leukemia (ALL) was investigated for possible correlation with clinical features at diagnosis and treatment outcome. Aven expression was found to be higher in patients >or=10...
journal_title：Leukemia research
pub_type： 杂志文章
doi：10.1016/j.leukres.2005.11.001
更新日期：2006-08-01 00:00:00
abstract：:We describe the properties of three monoclonal antibodies (McAbs) (21H73, 37G7 and 49C12) against K562 cell surface antigens correlated with differentiation induced by 12-O-tetradecanoyl phorbol-13-acetate (TPA). Each of the McAbs immunoprecipitated K562 cell surface antigen with molecular weight (MW) of approximately...
journal_title：Leukemia research
pub_type： 杂志文章
doi：10.1016/0145-2126(91)90121-9
更新日期：1991-01-01 00:00:00
abstract：:Useful prognostic markers for patients with diffuse large B cell lymphoma (DLBCL) have been reported. To identify which biomarker best predicts the prognosis of patients with DLBCL, we performed a retrospective study that included 319 DLBCL patients who had received rituximab, cyclophosphamide, doxorubicin, vincristin...
journal_title：Leukemia research
pub_type： 杂志文章
doi：10.1016/j.leukres.2015.08.016
更新日期：2015-08-29 00:00:00
abstract：:Medullary dyserythropoiesis with reduced production of erythrocytes is an early and consistent feature of myelodysplastic syndromes (MDS). The mechanism underlying the disturbed red cell proliferation and maturation is presently unknown. In order to study the role of erythropoietic growth factors, we determined by rad...
journal_title：Leukemia research
pub_type： 杂志文章
doi：10.1016/0145-2126(91)90025-o
更新日期：1991-01-01 00:00:00
abstract：:We report the establishment and characterization, including HLA-typing, immunophenotypic and molecular cytogenetic analysis, of a novel EBV-negative cell line (BLUE-1) derived from adult relapsed sporadic Burkitt lymphoma. BLUE-1 carries the pathognomonic t(8;14)(q24;q32) effecting MYC/IgHJ fusion and a novel t(6;20)(...
journal_title：Leukemia research
pub_type： 杂志文章
doi：10.1016/j.leukres.2006.03.026
更新日期：2006-11-01 00:00:00
abstract：:The mechanism of the inhibition of proliferation of human leukaemia 60 (HL60) cells by S-D-lactoylglutathione in vitro was investigated. The median inhibitory concentration IC50 value was 66 microM (95% C.I. 50-87 microM; n = 18). The inhibition of leukaemia cell growth required exposure of HL60 cells to S-D-lactoylgl...
journal_title：Leukemia research
pub_type： 杂志文章
doi：10.1016/0145-2126(93)90017-f
更新日期：1993-04-01 00:00:00
abstract：:Ten patients with acute nonlymphocytic leukemia (ANLL) received bromodeoxyuridine (BrdU) at 100 mg/M2 intravenously over 1 h. BrdU is incorporated into the DNA by S-phase cells and was detected by using a monoclonal anti-BrdU antibody in the bone marrow aspirate (BM) and biopsy specimens obtained at the end of the inf...
journal_title：Leukemia research
pub_type： 杂志文章
doi：10.1016/0145-2126(87)90160-3
更新日期：1987-01-01 00:00:00
abstract：:In this study, the expression and functional characterization of currents through the CFTR (cystic fibrosis transmembrane regulator) and ORCC (outwardly rectifying chloride channels) were determined in wild-type K562 chronic human leukemia cells (K562-WT) and in its resistant counterpart, the vincristine resistant cel...
journal_title：Leukemia research
pub_type： 杂志文章
doi：10.1016/j.leukres.2005.02.007
更新日期：2005-09-01 00:00:00
abstract：:Apoptosis resistance is an important mechanisms of drug resistance mediated by bone marrow stromal cells (BMSCs). BMSCs influence tumor cells survival through several mechanisms including direct cell-cell contact and the effects of soluble factors. In this research we investigated the role of X-linked inhibitor of apo...
journal_title：Leukemia research
pub_type： 杂志文章
doi：10.1016/j.leukres.2006.09.006
更新日期：2007-08-01 00:00:00
abstract：:Pro-apoptotic signalling upon toll-like receptor (TLR) stimulation in myeloid cells is normally antagonized by the simultaneous activation of anti-apoptotic pathways. We have previously reported that IFN-alpha can sensitize human monocytes to apoptosis induction by lipopolysaccharide (LPS). Based on these results we i...
journal_title：Leukemia research
pub_type： 杂志文章
doi：10.1016/j.leukres.2007.05.001
更新日期：2007-12-01 00:00:00
abstract：:The biochemical activity of terminal transferase (TdT) in the thymocytes of leukemic AKR mice has no relationship to cell cycle stage, unlike the activity of replicative DNA polymerase which increases during the period of DNA synthesis. Moreover, such assays of DNA polymerase alpha reveal a shift in enzyme activity fr...
journal_title：Leukemia research
pub_type： 杂志文章
doi：10.1016/0145-2126(84)90082-1
更新日期：1984-01-01 00:00:00
abstract：:Molecular epidemiological studies have found new insights into the etiology of myelodysplastic syndromes (MDS). We analyzed the polymorphisms of 5 genes in 275 patients with primary MDS and 354 healthy controls in an attempt to identify candidate genetic risk factors for primary MDS in Chinese Han population. There wa...
journal_title：Leukemia research
pub_type： 杂志文章
doi：10.1016/j.leukres.2010.12.001
更新日期：2011-06-01 00:00:00
abstract：:This study was aimed to illustrate the significance of minimal residual disease (MRD) assessment on day 22 in childhood acute lymphoblastic leukemia. MRD were measured on day 22, day 36, week 12, month 6 and month 12 by four-color flow cytometry. The 5-year cumulative incidence of relapse was significantly different f...
journal_title：Leukemia research
pub_type： 临床试验,杂志文章
doi：10.1016/j.leukres.2012.03.014
更新日期：2012-08-01 00:00:00
abstract：:In vivo infection by HTLV-I is characterized by the lack of virus expression in the host's infected cells and in most cases it is clinically inapparent. The present study shows that exposure of HTLV-I-infected human T-cells to a maximal non-toxic dose of 3-MC remarkably enhances virus expression. This stimulatory effe...
journal_title：Leukemia research
pub_type： 杂志文章
doi：10.1016/0145-2126(93)90098-6
更新日期：1993-05-01 00:00:00
abstract：:FcRIII (CD16) expression on neutrophils from 17 patients with chronic myeloid leukemia (CML) was studied by flow cytometry using monoclonal antibodies. A variable proportion of CD16-negative neutrophils were found both in CML patients in chronic phase (3 out of 8 patients) and in CML patients in hematological remissio...
journal_title：Leukemia research
pub_type： 杂志文章
doi：10.1016/0145-2126(92)90120-v
更新日期：1992-12-01 00:00:00
abstract：:A double monoclonal component (MC) detected in the serum and/or urine represents a very rare occurrence (2-6% of monoclonal gammopathies). In this study, we report 34 patients with double serum MCs, focusing on the associated diseases. The diagnosis was made using high-resolution serum protein electrophoresis and immu...
journal_title：Leukemia research
pub_type： 杂志文章
doi：10.1016/j.leukres.2012.05.008
更新日期：2012-10-01 00:00:00
abstract：:We report a unique case of chronic myelocytic leukemia (CML) with the Philadelphia (Ph) chromosome. The patient obtained cytogenetic complete remission (CR) after treatment with interferon (IFN). When he transformed to acute lymphocytic leukemia (ALL), cytogenetic analysis showed that the karyotype was normal and fluo...
journal_title：Leukemia research
pub_type： 杂志文章
doi：10.1016/s0145-2126(02)00175-3
更新日期：2003-04-01 00:00:00
abstract：:We have recently described that a variant of L1210 leukemia cell (L1210/LN-1) originally fused with Lesch-Nyhan fibroblast is highly immunogenic for inducing tumor-specific transplantation immunity in (BALB/cxDBA/2)F1 mice. This finding has clearly been confirmed in the present study by in-vitro cell-mediated cytotoxi...
journal_title：Leukemia research
pub_type： 杂志文章
doi：10.1016/0145-2126(85)90316-9
更新日期：1985-01-01 00:00:00
abstract：:Leukaemic cells from the peripheral blood of 90 patients with acute leukaemia (54 non-lymphocytic (ANLL) 36 lymphocytic (ALL)) have been examined for the presence of the platelet/ALL-associated p24 membrane antigen by indirect immunofluorescence and flow cytometry using monoclonal antibody FMC8. Cells from 28 of the A...
journal_title：Leukemia research
pub_type： 杂志文章
doi：10.1016/0145-2126(87)90109-3
更新日期：1987-01-01 00:00:00
abstract：:We have analysed the configuration of immunoassociated genes and the karyotypes of 30 patients with acute myelocytic leukemia (AML) and 10 with chronic myelocytic leukemia in blast crisis (CML-BC). In AML, the frequencies of T-cell receptor (TcR) beta, gamma, and delta chain and immunoglobulin heavy and light chain ge...
journal_title：Leukemia research
pub_type： 杂志文章
doi：10.1016/0145-2126(91)90070-a
更新日期：1991-01-01 00:00:00
abstract：:Aggressive systemic mastocytosis (ASM) is a hematopoietic neoplasm characterized by infiltration of visceral organs by neoplastic mast cells (MCs) with consecutive organopathy and respective clinical and laboratory findings (so called C-Findings). Whereas, it is generally appreciated that patients with ASM are candida...
journal_title：Leukemia research
pub_type： 杂志文章,评审
doi：10.1016/s0145-2126(03)00259-5
更新日期：2004-03-01 00:00:00
abstract：:The aims were to investigate the feasibility of imatinib mesylate (IM) discontinuation in chronic myeloid leukemia patients who were initially treated with IM and achieved complete molecular response (CMR). Fourteen patients were included. Ten were relapsed within 9.5 months after discontinuation of IM. All 7 patients...
journal_title：Leukemia research
pub_type： 杂志文章,多中心研究
doi：10.1016/j.leukres.2012.02.011
更新日期：2012-06-01 00:00:00
abstract：:We performed a comprehensive cost calculation identifying the main cost drivers of treatment of chronic lymphocytic leukaemia in daily practice. In our observational study 160 patient charts were reviewed repeatedly to assess the treatment strategies from diagnosis till the study end. Ninety-seven patients (61%) recei...
journal_title：Leukemia research
pub_type： 杂志文章
doi：10.1016/j.leukres.2013.10.029
更新日期：2014-01-01 00:00:00
